US equities
|
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by CG Oncology, Inc.
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 30, 2024
From
CG Oncology, Inc.
Via
Business Wire
Tickers
CGON
CG Oncology Announces Pricing of Upsized Initial Public Offering
January 24, 2024
From
CG Oncology, Inc.
Via
Business Wire
CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
December 05, 2023
From
CG Oncology, Inc.
Via
Business Wire
Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients With High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
November 30, 2023
From
CG Oncology, Inc.
Via
Business Wire
CG Oncology Announces Presentation of the First Phase 3 Monotherapy Data for Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC Patients at SUO 2023
November 14, 2023
From
CG Oncology, Inc.
Via
Business Wire
CG Oncology Announces Key Executive Appointments in Commercialization, Medical and Manufacturing Operations
September 05, 2023
From
CG Oncology, Inc.
Via
Business Wire
CG Oncology Completes Patient Enrollment in BOND-003 Phase 3 Monotherapy Study with Cretostimogene Grenadenorepvec in BCG-Unresponsive High-Risk NMIBC
July 24, 2023
From
CG Oncology, Inc.
Via
Business Wire
CG Oncology Announces New Phase 2 Data with Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA® (pembrolizumab) in BCG-Unresponsive NMIBC
May 01, 2023
From
CG Oncology, Inc.
Via
Business Wire
New Phase 2 Data With Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA® (pembrolizumab) in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting
April 10, 2023
From
CG Oncology, Inc.
Via
Business Wire
CG Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 27, 2022
From
CG Oncology, Inc.
Via
Business Wire
CG Oncology Raises $120 Million in Oversubscribed Series E Financing to Advance Clinical-Stage Urologic Oncology Pipeline
November 15, 2022
From
CG Oncology, Inc.
Via
Business Wire
CG Oncology Presents New Phase 2 Data With CG0070 in Combination With KEYTRUDA® (pembrolizumab) in Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin
November 10, 2022
From
CG Oncology, Inc.
Via
Business Wire
CG Oncology Presents New Clinical Data on Two Ongoing Programs at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
June 04, 2022
From
CG Oncology, Inc.
Via
Business Wire
CG Oncology Presents Additional Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
May 16, 2022
From
CG Oncology, Inc.
Via
Business Wire
CG Oncology Presents Interim Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
April 13, 2022
From
CG Oncology, Inc.
Via
Business Wire
CG Oncology Announces First Patient Dosed in Japan in Phase 3 Monotherapy Study of CG0070 in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
December 20, 2021
From
CG Oncology, Inc.
Via
Business Wire
CG Oncology Presents Preliminary Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin
November 13, 2021
From
CG Oncology, Inc.
Via
Business Wire
CG Oncology to Present Two Programs at The Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
October 12, 2021
From
CG Oncology, Inc.
Via
Business Wire
CG Oncology and Roche to Collaborate on Clinical Trial of Oncolytic Immunotherapy CG0070 as Part of Novel Combination for Various Solid Tumor Indications
September 22, 2021
From
CG Oncology, Inc.
Via
Business Wire
CG Oncology Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Oncolytic Immunotherapy CG0070 in Combination with OPDIVO® (nivolumab) in Metastatic Urothelial Cancer
September 09, 2021
From
CG Oncology, Inc.
Via
Business Wire
